Amarin Corp Plc (AMRN)

[HDGabor]

I think it useless to evaluate the agreement now, however the timing is not unintelligible:

“As previously described, our goal is to achieve net cash outflow of not more than $80 million in 2014 and to make our cash flat.”

“The Kowa team should be before the end of this month be fully trained out and promoting Vascepa. They will have the advantage in getting started that they already have relationships with customers.”

„ …submitting a round of appeal in the next line of review with FDA, which is John Jenkins the head of the Office of New Drugs. And then we'll probably end up meeting with him 30 days after we submit. And then after that, he should get back to us within another 30 days. So given where we are in this and how long it takes to go through the process and delays that have occurred thus far and as part of that process, our plan is to provide updates on at least a quarterly basis, but unless there's a significant change in status we probably just update on the quarterly call.”

Why it was necessary now and not in August /September, when we will have some idea about KOWA effect and we will know the OND’s decision.